RIGImmune’s innovative nanoemulsion non-lipid nanoparticle (LNP) delivery platform provides versatile delivery of SLRs through intranasal and intrapulmonary administration. Drug delivery is critical to therapeutic success, and RIGImmune’s novel delivery platform penetrates the respiratory epithelium, which usually presents a significant barrier, for efficient intracellular delivery. The delivery system has been well-tolerated in preclinical trials, localizes to the RIG-I target, and facilitates a low and effective drug load through cellular uptake.